15:32 , Jun 8, 2018 |  BC Week In Review  |  Company News

Axovant reboots with gene therapy deal

Months after a clinical failure in Alzheimer's disease destroyed most of its value, Axovant Sciences Ltd. (NASDAQ:AXON) is seeking a path forward by obtaining rights to a gene therapy for Parkinson's disease. Oxford BioMedica plc (LSE:OXB)...
14:00 , Jun 6, 2018 |  BC Extra  |  Company News

Axovant reboots with gene therapy deal

Months after a clinical failure in Alzheimer's disease destroyed most of its value, Axovant Sciences Ltd. (NASDAQ:AXON) is seeking a path forward by obtaining rights to a gene therapy for Parkinson's disease. Oxford BioMedica plc (LSE:OXB)...
07:00 , Mar 9, 2015 |  BioCentury  |  Emerging Company Profile

AAVs for the CNS

Voyager Therapeutics Inc. has a pipeline of adeno-associated viral vector-based gene therapies and is developing novel vectors that are optimized for better distribution in the CNS, among other qualities. Third Rock Ventures launched Voyager about...